---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-042938"
form_type: "8-K"
ticker: "NMTC"
cik: "0001500198"
company_name: "NEUROONE MEDICAL TECHNOLOGIES Corp"
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:43:39.400685+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NeuroOne Q2 FY2024 product revenue triples to $1.38M; OneRF ablation system launched

## Summary
- Product revenue $1.38M in Q2 2024, up from $466K in Q2 2023.
- Net loss narrowed to $2.9M vs $3.5M a year ago; six-month net loss $6.2M.
- Cash and cash equivalents $2.4M as of March 31, 2024, down from $5.3M at Sept 30, 2023.
- Initiated limited commercial launch of OneRF Ablation System in late March; 5 patients implanted.
- Zimmer Biomet continued expanding sEEG electrode accounts; raised $2.0M via ATM in Q2.

## SEC filing metadata
- accession: 0001213900-24-042938
- form_type: 8-K
- ticker: NMTC
- cik: 0001500198
- company_name: NEUROONE MEDICAL TECHNOLOGIES Corp
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1500198/000121390024042938/0001213900-24-042938-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1500198/000121390024042938/ea0205728-8k_neuro.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-042938
- JSON: https://secwatch.observer/filing/0001213900-24-042938.json
- Plain text: https://secwatch.observer/filing/0001213900-24-042938.txt

## Key facts
- Earnings Releases
  NEUROONE MEDICAL TECHNOLOGIES Corp reported second quarter fiscal year 2024 ended March 31, 2024 results: revenue $1,377,000, net income $2.9 million.
  - Period: second quarter fiscal year 2024 ended March 31, 2024
  - Revenue: $1,377,000
  - Net income: $2.9 million
  - Result: reported results
  source text: results for the second quarter fiscal year 2024 ended March 31, 2024. Second Quarter Fiscal Year 2024 and Recent Business Updates Financial Highlights: ● Product revenue of $1,377,000 in Q2 2024, compared to $466,000 in Q2 2023 ● Raised an additional $2.0 million using the ATM Program in Q2 2024 Evo ® sEEG: ● Zimmer Biomet continued to expand into new
  evidence_url: https://www.sec.gov/Archives/edgar/data/1500198/000121390024042938/0001213900-24-042938-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.